Welcome to The Medical Roundtable

Expert Experience Interpreting Evidenced-Based Medicine.

Our experts provide their decades of clinical practice and trial experience in a conversational based format that create a compelling discussion.

Don't miss our Clinical Implications and QuizBank to help your improve your knowledge and practice.

Heard at the Roundtable

  • “Ezetimibe has a role for LDL cholesterol lowering when other options have been exhausted. A change in this approach will require compelling evidence from a clinical events trial.”
    ~ Robert S. Rosenson, MD

  • “Aspirin is said to minimize the flushing that occurs with the niacin products. Many of the patients we would consider candidates for niacin need to be on aspirin anyway because they’re high-risk.”
    ~ Peter H. Jones, MD

  • "HF [heart failure] is slightly more common in women—just over half of the HF population—and they certainly have more hypertension than we ever expected."

    W. Frank Peacock, MD

  • "It seems like the biggest change in the guidelines is the addition of ticagrelor, or BRILINTA®.… a new antiplatelet therapy that has been shown to be effective in ACS. Actually, based on the PLATO trial and the current [US FDA] rulings, it’s the only antiplatelet agent that is superior to clopidogrel for reducing cardiovascular death following ACS.…"

    Carl J. Lavie, MD

  • “Most of the time we’re talking about an absolute difference in diabetes incidence within these trials of a couple percent.”
    ~ Bill Cushman, MD